Is CC a Buy or a Sell? The Bull and Bear Case (2026)

Last updated October 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for The Chemours Company (CC) rests on Opteon refrigerant growth: The Thermal & Specialized Solutions segment, anchored by Opteon low-GWP refrigerants, is Chemours' clearest growth engine. The bear case rests on pFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the federal and North Carolina settlements already reached in 2026. Analysts covering it publish targets from $14.00 to $24.00 against a $12.74 price, so even the professionals disagree by 59% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

The Chemours Company is a US-listed specialty chemicals producer spun out of DuPont in 2015. It reports through three segments: Thermal & Specialized Solutions (refrigerants and thermal management, led by the Opteon low-global-warming-potential product line), Titanium Technologies (TiO2 white pigment used in paints, plastics, and paper), and Advanced Performance Materials (high-end fluoropolymers and advanced materials). Trailing twelve-month revenue is roughly $5.8 billion, about the same as full-year 2025, and the company operates globally across industrial, construction, automotive, and electronics end markets with about 5,700 employees. The investment picture is a barbell. Opteon refrigerants are benefiting from the regulatory phase-down of higher-emission HFCs under the AIM Act, giving Chemours a structurally growing, higher-margin franchise. Against that, the Titanium Technologies business is deeply cyclical and has faced soft pricing and demand tied to construction and coatings, while the company carries substantial, widely reported PFAS environmental and litigation liabilities. Chemours reached a roughly $450 million federal PFAS settlement with the EPA earlier in 2026, and in September 2026 Chemours, DuPont, and Corteva agreed a $455 million settlement with North Carolina and 11 local entities over Fayetteville Works discharges, paid over 15 years. AFFF multi-district litigation and other claims remain unresolved, keeping the balance sheet and legal exposure central to how the stock trades. The second quarter of 2026 (reported in August) brought revenue of about $1.59 billion and adjusted EPS of $0.42, exactly in line with consensus, but a GAAP net loss of about $274 million. Since then the stock has slid: as of October 16, 2026 it closed at $13.03, up about 6 percent year to date but down about 5 percent over one year and about 27 percent over three months, after RBC downgraded the shares on persistent TiO2 weakness and cut its target to $14 from $22. The next quarterly report is expected around November 5, 2026.

The bull case: what would have to be true for $24.00

The most optimistic published target on CC is $24.00, +88.4% from the $12.74 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Opteon refrigerant growth

The Thermal & Specialized Solutions segment, anchored by Opteon low-GWP refrigerants, is Chemours' clearest growth engine. Regulatory HFC phase-downs under the AIM Act and similar rules abroad are shifting demand toward the newer chemistries Chemours produces. Near-term momentum has cooled: in October 2026 RBC flagged that the segment could face headwinds until year-end. Analysts on average expect 2026 revenue of about $5.92 billion, roughly 2 percent above 2025, rising to about $6.2 billion in 2027.

2. TiO2 pigment cyclical recovery

Titanium Technologies is the largest revenue segment and is highly sensitive to construction, coatings, and industrial demand. Pricing and volumes have stayed under pressure through 2026, and persistent TiO2 weakness was the stated reason for RBC's October downgrade. Any recovery in global coatings demand or pigment pricing would be a meaningful earnings lever, while continued weakness keeps consolidated margins thin (operating margin is about 1 percent on a trailing basis).

3. Cost, cash flow, and dividend

Chemours has emphasized cost discipline, capital-expenditure control, and free cash flow conversion. Trailing free cash flow is about $300 million against EBITDA of about $485 million. The company pays a dividend of about $0.35 per share annually, a yield near 2.7 percent at the current price, which is high relative to its GAAP losses. Leverage is the constraint: about $4.1 billion of debt against roughly $670 million of cash.

4. PFAS liability resolution

Progress on resolving PFAS exposure is itself a potential catalyst. The federal EPA settlement of about $450 million and the September 2026 North Carolina settlement of $455 million (Chemours pays half under a 2021 cost-sharing agreement with DuPont and Corteva, roughly $50 million expected over the next 12 months) removed some uncertainty at legacy sites. Further settlements or favorable outcomes in the remaining AFFF litigation could reduce the discount the market applies, though the timing and size of remaining liabilities are uncertain.

The bear case: what would have to be true for $14.00

The most pessimistic published target is $14.00, +9.9% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks The Chemours Company is worth if the risks below bite instead of the drivers above.

PFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the federal and North Carolina settlements already reached in 2026. The Titanium Technologies segment is cyclical and exposed to weak construction and coatings demand plus low-cost pigment competition, and analysts cut targets in October 2026 on exactly that weakness. The company posted GAAP net losses in each of the last three reported quarters, including about $274 million in Q2 2026, for a trailing net loss of about $304 million. Debt of about $4.1 billion and the cash demands of legal settlements constrain financial flexibility, and the dividend currently exceeds GAAP earnings. Regulatory, raw-material, and currency swings add further volatility to results. Walnut is not an investment adviser; this page describes the business and is not a recommendation.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding CC already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on CC

10 analysts cover CC, with an average target of $16.90 (+32.7% against $12.74) and a split of 2 buy, 8 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the CC forecast and price target page.

How is CC valued? (as of October 2026)

Price

$12.74

Market cap

$1.92B

Forward P/E

6.81

Beta

1.40

52-week range

$10.44 to $28.67

Snapshot for CC as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$5.8B
Revenue growth (latest qtr, YoY): ~-1.5%
Net income (TTM): ~-$304M
Q2 2026 adj. EPS vs est.: $0.42 vs $0.42
Forward P/E: ~7x
EV/EBITDA: ~11x
Market cap: ~$2.0B
Dividend yield: ~2.7%

At about $13 a share, Chemours is valued at roughly $2 billion, or about 0.34 times its ~$5.8 billion revenue, a cyclical-and-litigation discount rather than a growth multiple. There is no trailing P/E because of GAAP losses, while the forward P/E of about 7 rests on analysts' 2027 EPS estimate of about $1.87 nearly doubling 2026's. EV/EBITDA near 11 shows how much of the enterprise value sits in roughly $4.1 billion of debt; consensus for the Q3 report (expected around November 5) is EPS of about $0.26 on revenue of about $1.53 billion.

How do you decide if CC is a buy?

Rather than asking whether CC is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold CC indirectly through an index or sector ETF before adding more.

What would change your mind on CC

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: Opteon refrigerant growth stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: pFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the federal and North Carolina settlements already reached in 2026 fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the CC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CC against your real portfolio and see your actual exposure before deciding.

Investing in The Chemours Company with AI

Connect the broker you already use and ask Walnut's AI how CC fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does CC fit me?

FAQ

Is CC a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on Opteon refrigerant growth, with revenue (ttm) at ~$5.8B. The bear case rests on pFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the federal and North Carolina settlements already reached in 2026. Analysts covering it are spread from $14.00 to $24.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell CC?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. PFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the federal and North Carolina settlements already reached in 2026. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $14.00, +9.9% from the $12.74 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for CC?

Opteon refrigerant growth. The Thermal & Specialized Solutions segment, anchored by Opteon low-GWP refrigerants, is Chemours' clearest growth engine. The most optimistic analyst target on CC is $24.00, +88.4% from the $12.74 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for CC?

What does The Chemours Company do?

The Chemours Company is a US-listed specialty chemicals producer spun out of DuPont in 2015.

What would have to change for CC to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Opteon refrigerant growth) stalling in the reported numbers rather than in the narrative, the risk above (pFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the federal and North Carolina settlements already reached in 2026) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Chemours do?

Chemours is a US specialty chemicals company that makes TiO2 white pigment, Opteon low-global-warming-potential refrigerants, and advanced fluoropolymers. It was spun out of DuPont in 2015 and sells into coatings, plastics, refrigeration, automotive, and industrial markets worldwide.

What are Chemours' business segments?

The company reports three segments: Thermal & Specialized Solutions (refrigerants and thermal management), Titanium Technologies (TiO2 pigment), and Advanced Performance Materials (fluoropolymers and advanced materials), plus a smaller Performance Chemicals and Intermediates business.

How much revenue does Chemours generate?

Chemours reported full-year 2025 net sales of roughly $5.8 billion, about flat versus 2024, and trailing twelve-month revenue as of mid-2026 is also about $5.8 billion. Quarterly revenue was about $1.38 billion in Q1 2026 and about $1.59 billion in Q2 2026, with the latest quarter down about 1.5 percent year over year.

Walnut is informational, not investment advice, and gives no verdict on CC. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.